Skip to content
  • BTC $58,467 −6.4%
  • ETH $1,606 −9.4%
  • SOL $68.04 −7.6%
  • BNB $534.79 −8.4%
  • XRP $0.8941 −7.6%
  • DOGE $0.0531 −9.5%
  • ADA $0.1395 −8.9%

Sun Pharma organon deal lifts Organon on $11.75B all-cash bid

Sun pharma organon deal lifts Organon shares as investors weigh the $11.75 billion cash offer, debt load and biosimilars reach.

sun pharma organon
Sun Pharma Organon deal boosts shares in $11.75B bid

Organon shares jumped again after Sun Pharma confirmed a sun pharma organon deal worth $11.75 billion, including debt. The all-cash offer values each share at $14.00, and the stock has climbed about 46% since the first reports.

Deal terms and market reaction

Initial reports said Sun Pharma was in talks to buy Organon for about $13 billion. However, the official terms pushed the shares higher in premarket trading, as investors reacted to the final price and structure.

The boards of both companies approved the transaction unanimously. Moreover, Sun Pharma said it will finance the purchase with existing cash and secured banking facilities.

Why Organon matters to Sun Pharma

Organon became an independent company in 2021 after a spinoff from Merck. It focuses on women’s healthcare, biosimilars, and established brand pharmaceuticals.

In 2025, Organon reported $6.2 billion in revenue and adjusted EBITDA of $1.9 billion. The company also operates in the United States, Europe, China, Canada, and Brazil.

Moreover, its footprint includes six production facilities across the European Union and developing markets. Sun Pharma would gain access to more than 70 pharmaceutical products sold across over 140 countries.

Strategy, leverage and outlook

Analysts said the combined company should lift the share of revenue from innovative products versus Sun Pharma’s current mix. That said, the move also expands the group’s women’s health lineup and deepens its reach in the global women’s healthcare sector.

In another sign of scale, the combined business is expected to become the seventh-largest player globally in the biosimilars market. The deal also strengthens Sun Pharma’s position in the biosimilars market growth story, while broadening its therapeutic base.

On financing, Organon enters the transaction with substantial debt of $8.6 billion and cash reserves of $574 million as of December 2025. Its net debt-to-EBITDA multiple stood at 4x before the announcement, while analysts expect that ratio to improve to an estimated 2.3x after completion.

However, the transaction still needs regulatory approvals and shareholder consent. The companies expect the acquisition to close in early 2027. This cross border acquisition marks one of the biggest recent moves in pharma takeover news and underscores the scale of the organon acquisition deal.

Sun Pharma’s planned purchase of Organon combines scale, cash flow and geographic reach in one move. If approved, the sun pharma merger would create a broader platform across biosimilars, women’s health and established brands.

Amelia Tomasicchio

As expert in digital marketing, Amelia began working in the fintech sector in 2014 after writing her thesis on Bitcoin technology. Previously author for several international crypto-related magazines and CMO at Eidoo. She is now the co-founder of The Cryptonomist. She is also a marketing teacher at Digital Coach in Milan and she published a book about NFTs for the Italian publishing house Mondadori, while she is also helping artists and company to entering in the sector. As advisor, Amelia is also involved in metaverse-related project such as The Nemesis and OVER.

All articles by Amelia Tomasicchio